You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 140 No. 3, March 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Thyrotropin-Receptor Autoantibodies in Children and Young Adults With Graves' Disease

Rosalind S. Brown, MD, CM; Louis P. Kertiles, MS; Cathy Rosenfield, MD; Richard E. Kleinmann, MD; John F. Crigler, Jr, MD

Am J Dis Child. 1986;140(3):238-241.


Abstract

• Thyrotropin (TSH)-receptor autoantibodies were assessed by measurement of125l-bTSH binding inhibition in 32 patients with juvenile-onset Graves' disease (one of whom was studied twice) and 16 normal control subjects. Thirteen (76.5%) of 17 thyrotoxic patients had significantly elevated TSH binding-inhibitory immunoglobulin (TBII) activity compared with eight (50%) of 16 patients who were in clinical remission and none of the control subjects. Mean TBII activity was significantly greater in thyrotoxic patients than in individuals in remission, except in one unusual patient in whom there was a discordance between TBII activity and in vitro thyroid-stimulatory activity. In eight euthyroid patients who were followed up for at least five months while not receiving treatment, assessment of TBII activity did not predict who would or would not suffer relapse at a later date. Thus, TBIIs are secreted in excess in juvenile Graves' disease, the titer decreasing as the disease remits. The TBII assay cannot be used as the sole predictor of when antithyroid medication can be withdrawn safely, however.

(AJDC 1986;140:238-241)



Author Affiliations

From the Departments of Pediatrics (Drs Brown and Rosenfield and Mr Kertiles) and Medicine (Dr Kleinmann), Division of Endocrinology, University of Massachusetts Medical School, Worcester; and the Department of Medicine Division of Endocrinology, The Children's Hospital, and the Department of Pediatrics, Harvard Medical School, Boston (Dr Crigler). Dr Kleinmann is now with the West Virginia University Medical Center, Charleston.


Footnotes

Accepted for publication Nov 5, 1985.

Presented in part at the Annual Meeting of the American Thyroid Association, San Diego, Nov 5-8, 1980.

Reprints not available.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.